MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection
1 other identifier
observational
280
1 country
1
Brief Summary
The goal of this observational study is to compare specific microRNA levels from the plasma of gastric cancer patients and healthy volunteers to see if there is an upregulated expression in gastric cancer patients. The main question it aims to answer is: \- Can microRNAs be effectively used as diagnostic biomarkers for gastric cancer? Participants will be asked for their consent to obtain 5 cc of blood.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 29, 2023
CompletedStudy Start
First participant enrolled
April 25, 2023
CompletedFirst Posted
Study publicly available on registry
June 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedJune 13, 2023
June 1, 2023
1.7 years
March 29, 2023
June 3, 2023
Conditions
Outcome Measures
Primary Outcomes (5)
The different of MiR-20a level between gastric cancer and control group
The different of MiR-20a level between gastric cancer and control group
Day 1
The different of MiR-21 level between gastric cancer and control group
The different of MiR-21 level between gastric cancer and control group
Day 1
The different of MiR-106b level between gastric cancer and control group
The different of MiR-106b level between gastric cancer and control group
Day 1
The different of MiR-199a level between gastric cancer and control group
The different of MiR-199a level between gastric cancer and control group
Day 1
The different of MiR-223 level between gastric cancer and control group
The different of MiR-223 level between gastric cancer and control group
Day 1
Study Arms (2)
Gastric Cancer
Control
Interventions
Eligibility Criteria
Patients from King Chulalongkorn Memorial Hospital Inclusion Criteria for Gastric Cancer group: * Recently diagnosed gastric cancer * Never received any treatment for gastric cancer Inclusion Criteria for Control group: * Age 50 or above * Underwent elective upper gastrointestinal endoscopy and negative for gastric cancer * No prior history of gastric dysplasia or cancer Exclusion Criteria: * Patients who cannot give informed consent * Pregnancy * Lymphoma
You may qualify if:
- Recently diagnosed gastric cancer
- Never received any treatment for gastric cancer
- Age 50 or above
- Underwent elective upper gastrointestinal endoscopy and negative for gastric cancer
- No prior history of gastric dysplasia or cancer
You may not qualify if:
- Patients who cannot give informed consent
- Pregnancy
- Lymphoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Chulalongkorn Memorial Hospital
Bangkok, Not Required For This Country, 10400, Thailand
Biospecimen
5 cc of blood will be obtained from each subject then the plasma portion will be collected.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 29, 2023
First Posted
June 13, 2023
Study Start
April 25, 2023
Primary Completion
January 1, 2025
Study Completion
June 1, 2025
Last Updated
June 13, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share